Clinical Utility of Oncofetal and Proteins and Hormones as Tumor Markers
- 1 November 1986
- journal article
- review article
- Published by Elsevier in Medical Clinics of North America
- Vol. 70 (6) , 1295-1306
- https://doi.org/10.1016/s0025-7125(16)30899-9
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Prolactin Stimulation of Maternal Behavior in Female RatsScience, 1985
- Prolactinomas.BMJ, 1985
- Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas.BMJ, 1985
- Prolactin response to thyrotropin-releasing hormone (TRH) in patients with hypothalamic-pituitary diseaseFertility and Sterility, 1985
- Testicular Carcinoma: A curable malignancyActa Radiologica: Oncology, 1985
- Value of β-subunit of human chorionic gonadotropin, pregnancy-specific β1-glycoprotein, and α-fetoprotein in preoperative evaluation of patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 1984
- Carcinoembryonic Antigen: Its Role as a Marker in the Management of Cancer. A National Institutes of Health Consensus Development ConferenceAnnals of Internal Medicine, 1981
- Decreased Bone Density in Hyperprolactinemic WomenNew England Journal of Medicine, 1980
- DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUESThe Journal of Experimental Medicine, 1965
- Demonstration of a New Protein Fraction in Serum from the Human FetusScandinavian Journal of Clinical and Laboratory Investigation, 1956